SolastoTSE:6197 59 Net Margin % is 0.48% as of Mar. 2026, which is 85% below its 10-year median of 3.16. GuruFocus rates TSE:6197 with a GF Score™ of 59/100 and a GF Value™ of 円563.54 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Solasto ranks worse than 51.2% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Solasto's Net Income for the
three
months ended in Mar. 2026 was 円171 Mil. Solasto's Revenue for the
three
months ended in Mar. 2026 was 円35,520 Mil. Therefore, Solasto's net margin for the quarter that ended in Mar. 2026 was 0.48%.
The historical rank and industry rank for Solasto's Net Margin % or its related term are showing as below:
TSE:6197'
s Net Margin % Range Over the Past 10 Years
Min: 1.67 Med: 3.16 Max: 4.95
Current: 2.65
TSE:6197's Net Margin % is ranked worse than 51.2% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs TSE:6197: 2.65
Solasto (TSE:6197) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Solasto Net Margin % Related Terms
Solasto Net Margin % Historical Data
* Premium members only.
The historical data trend for Solasto's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6197 vs HCA, THC, DVA: Net Margin % Comparison
For the Medical Care Facilities subindustry, Solasto's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasto Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Solasto's Net Margin % distribution charts can be found below:
* The bar in red indicates where Solasto's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasto (TSE:6197) has a Net Margin % of 0.48% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Solasto and its competitors. This is 85% below median its historical median of 3.16. Over the past decade, Solasto's Net Margin % has ranged from 1.67 to 4.95. According to the industry distribution chart, Solasto ranks #342 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 51.2%.
Is Solasto's Net Margin % too high?
Solasto's current Net Margin % of 0.48% is 85% below median its 10-year median of 3.16. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 4.95. The Healthcare Providers & Services industry median Net Margin % is 2.89. Solasto's value of 0.48% is 83.4% below this industry median. Based on the distribution chart, Solasto ranks #342 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Solasto has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasto's Net Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Solasto ranks #342 out of 668 companies for Net Margin %. This places Solasto in the lower half of its industry. The industry median Net Margin % is 2.89. Solasto's value of 0.48% is 83.4% below this benchmark. Historically, Solasto's own Net Margin % has ranged from 1.67 to 4.95 over the past decade. While the company's 10-year median is 3.16 vs. the industry median of 2.89, Solasto has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasto's current Net Margin % of 0.48% is 83.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Solasto and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasto's current Net Margin % is 0.48%, which is 85% below median its own 10-year median of 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasto stock overvalued right now?
Based on GuruFocus' analysis, Solasto (TSE:6197) is currently considered Significantly Overvalued. The stock's GF Value™ is 円563.54, compared to a current price of 円1,109.00 — trading 96.8% above its estimated fair value. The current Net Margin % is 0.48%, which is 85% below median its 10-year median of 3.16 and 83.4% below the Healthcare Providers & Services industry median of 2.89. Solasto's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Solasto (TSE:6197), the current Net Margin % is 0.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasto (TSE:6197) Overvalued in 2026?
Based on GuruFocus' analysis, Solasto stock appears to be overvalued.
The current stock price of 円1,109.00 is trading 96.8% above its estimated GF Value™ of 円563.54.
GuruFocus considers Solasto to be Significantly Overvalued.
Key valuation signals for TSE:6197:
Net Margin %: 0.48% (85% below median its 10-year median of 3.16)
GF Value™: 円563.54 vs. price of 円1,109.00 (96.8% above fair value)
Industry Position: 83.4% below the Healthcare Providers & Services median (#342 of 668)
No single metric tells the full story. See the TSE:6197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6197 has been successfully added to your 
